http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110577514-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-517 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-517 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2019-05-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-07-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-07-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-110577514-B |
| titleOfInvention | Human epidermal growth factor receptor inhibitor and preparation method and application thereof |
| abstract | The present invention relates to a quinoline or a quinazoline derivative having the structure of formula (I), a pharmaceutical composition containing the compound of formula (I), and the preparation of said compound for preventing or treating human epidermal growth factor receptor Her/erbB family related diseases Use of a medicament, particularly for the prevention or treatment of tumors associated with protein tyrosine kinases. wherein each substituent in the formula (I) is as defined in the specification. |
| priorityDate | 2018-06-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 227.